Innate Pharma (IPHA) Operating Income (2020 - 2025)

Innate Pharma (IPHA) has reported Operating Income for 5 consecutive years, with -$28.9 million the latest figure, recorded in Q2 2025.

• Quarterly Operating Income rose 3.37% year-over-year to -$28.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was -$113.8 million (changed 0.0% YoY) and the FY2025 annual result came in at -$61.5 million, down 4.72% from the prior year.
• Operating Income grew to -$28.9 million in Q2 2025 per IPHA's latest filing, from -$29.9 million in the prior quarter.
• Over the last five years, Operating Income for IPHA reached as high as -$452905.8 in Q2 2023 and fell as low as -$54.4 million in Q4 2021.
• A 4-year average of -$28.5 million and a median of -$28.9 million in 2021 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2024 — Operating Income slumped 6511.31% — and 2025, when it grew 3.37%.
• Year by year, Operating Income stood at -$54.4 million in 2021, then soared by 99.17% to -$452905.8 in 2023, then tumbled by 6511.31% to -$29.9 million in 2024, then increased by 3.37% to -$28.9 million in 2025.
• According to Business Quant data, Operating Income over the past three periods registered -$28.9 million, -$29.9 million, and -$452905.8 for Q2 2025, Q2 2024, and Q2 2023 respectively.